QTTB Q32 Bio Inc.
Company Updates ·
Bempikibart showed a 35.3% mean reduction in SALT score at Week 36 in alopecia areata. The company intends to start a registration-directed program in the first half of 2027.
Both hires come as Q32 Bio prepares a registration-directed program for bempikibart in alopecia areata. The company plans to start it in the first half of 2027.
The company reported positive 36-week topline results for bempikibart and completed a $200.0 million public offering in July 2026.
Morgan Stanley, Jefferies, Cantor Fitzgerald and Oppenheimer are the representatives of the underwriters. The offering is expected to close on July 16, 2026.
Cash and cash equivalents were $50.8 million at March 31, 2026. The company received $14.2 million of at-the-market proceeds after the quarter ended.
Q32 Bio closed the asset sale on November 28, 2025 and is eligible for up to $580 million in milestones plus royalties. It now expects cash to fund operations into the second half of 2027.
The minimum stockholders' equity requirement is $2.5 million. Q32 Bio has 45 calendar days to submit a plan to regain compliance.
Q32 Bio is ending its renal trial of ADX-097, cutting staff and betting on bempikibart in alopecia areata. It expects about $1.1 million in severance charges and says cash should last into the second half of 2026, but the release gives no cash balance.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $53.7 million | $0 |
| Research and development | $19.2 million | $48.1 million |
| Net income (loss) | $29.8 million | -$47.7 million |
| Cash from operations | -$33.5 million | -$67.7 million |
| Cash and equivalents | $48.3 million | $78.0 million |
| Short-term investments | $0 |
Our latest story on this, dated Aug 5, 2026: "Q32 Bio reports Q2 2026 net loss of $8.9 million and $106.3 million cash". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 23, 2025: "Q32 Bio gets Nasdaq notice after reporting stockholders' deficit of ($4.0 million)". The story links the filing or release it is based on. Read the story.
Q32 Bio Inc. trades under the ticker QTTB on NASDAQ.
Q32 Bio Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:DB0; LSE:0T6G.
The SEC Central Index Key (CIK) for Q32 Bio Inc. is 1661998. Its filings are on SEC EDGAR.
29,769,466 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-05.
Our directory records Q32 Bio Inc. under United States.
Our directory classifies Q32 Bio Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Q32 Bio Inc. is US7469641051.
aibio.space lists Q32 Bio Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
$53.7 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.
Q32 Bio Inc. reported net income of $29.8 million for the fiscal year ended Dec 31, 2025, and used $33.5 million of cash in operations, per its annual report to the SEC.
$19.2 million in the fiscal year ended Dec 31, 2025, per its annual report.
$106.3 million in cash at Jun 30, 2026, per its 10-Q.
Reported a financing. SEC Form 8-K (Items 7.01,8.01,9.01). Source
Filed a final prospectus for a securities offering. SEC Form 424B5. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 424B5. Source
Reported a financing. SEC Form 424B5. Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,1.02,2.01,7.01,8.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source
Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio